✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Kabra Drugs Ltd.

KABRADG

Market Cap
₹58 Cr.
P/E
11.63

Kabra Drugs Ltd.

  • Kabra Drugs
  • Biofil Chem & Pharma
  • Bacil Pharma

FAQs on Kabra Drugs Ltd. Shareprice

Kabra Drugs has given better returns compared to its competitors.
Kabra Drugs has grown at ~75.11% over the last 2yrs while peers have grown at a median rate of -6.14%

Kabra Drugs is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Kabra Drugs is 11.63, while 3 year average PE is 13.5.
Also latest EV/EBITDA of Kabra Drugs is 9.04 while 3yr average is 8.04.

View FAQ's On Business

Growth Table

  • Kabra Drugs Ltd.
  • Biofil Chem & Pharma
  • Bacil Pharma

Balance Sheet

  • Kabra Drugs Ltd.
  • Biofil Chem & Pharma
  • Bacil Pharma

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Kabra Drugs Ltd.
  • Biofil Chem & Pharma
  • Bacil Pharma

Cash Flow

  • Kabra Drugs Ltd.
  • Biofil Chem & Pharma
  • Bacil Pharma

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Kabra Drugs Ltd.
  • Biofil Chem & Pharma
  • Bacil Pharma

Quarterly Results

  • Kabra Drugs Ltd.
  • Biofil Chem & Pharma
  • Bacil Pharma

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Kabra Drugs Ltd. Financials

Balance sheet of Kabra Drugs is moderately strong.

Yes, The net debt of Kabra Drugs is increasing.
Latest net debt of Kabra Drugs is -₹10.15 Crs as of Mar-26.
This is greater than Mar-25 when it was -₹42.04 Crs.

The profit is oscillating.
The profit of Kabra Drugs is ₹4.97 Crs for TTM, -₹1.09 Crs for Mar 2025 and -₹0.74 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Kabra Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech